ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
69.09
-1.82 (-2.57%)
At close: Aug 6, 2025, 4:00 PM
69.55
+0.46 (0.67%)
After-hours: Aug 6, 2025, 7:39 PM EDT
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.60 |
| CIK Code | 0001956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Didier Scherrer Ph.D. | Chief Scientific Officer |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development and Manufacturing |
| Hema Keshava | Senior Vice President of Finance |
| Chris Rabbat Ph.D. | Vice President and Global Head of Medical Affairs |
| Kevin Shan Ph.D. | Vice President and Global Head of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | SCHEDULE 13D/A | Filing |
| Jul 24, 2025 | 424B5 | Filing |
| Jul 24, 2025 | 6-K | Report of foreign issuer |
| Jul 24, 2025 | FWP | Free Writing Prospectus |
| Jul 23, 2025 | FWP | Free Writing Prospectus |
| Jul 23, 2025 | 424B5 | Filing |
| Jul 23, 2025 | F-3ASR | Filing |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jun 11, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |